Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-05-03

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)

View source ↗

Summary

FDA granted approval of Dr. Reddy's supplemental application for buprenorphine/naloxone; this generic product is approved for the treatment of opioid use disord…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)